...
首页> 外文期刊>Pharmaceutical sciences. >Fast Dissolving Sublingual Films Containing Sumatriptan Alone and Combined with Methoclopramide: Evaluation in Vitro Drug Release and Mucosal Permeation
【24h】

Fast Dissolving Sublingual Films Containing Sumatriptan Alone and Combined with Methoclopramide: Evaluation in Vitro Drug Release and Mucosal Permeation

机译:速溶单独含有舒马曲坦并结合甲氧氯普胺的舌下薄膜:体外药物释放和粘膜渗透的评估

获取原文

摘要

Background: Sumatriptan succinate is a 5-HT1 receptor agonist which is used in the treatment of migraine. It shows low bioavailability (15%) due to high hepatic first pass metabolism. The present work intended to formulate mucoadhesive sublingual films of sumatriptan combined with metoclopramide and sumatriptan alone with the objective of improving the therapeutic efficacy, patient compliance, and bioavailability. Methods: The sublingual films were formulated by solvent casting technique using mucoadhesive polymer of hydroxypropyl methylcellulose and propylene glycol as plasticizers. This study was also designed to evaluate the physicochemical and mucoadhesive characteristics of the films. The films were evaluated for their mechanical strength, folding endurance, drug content uniformity, swelling, in vitro residence time, in vitro release, in vitro bioadhesion, and in vivo mucoadhesion. Results: They showed good appearance and elasticity. The best drugs of polymer ratio were S3 (1:2) and SM2 (2.7:1:8). The film of S3 and SM2 showed 10.6 and 11.01 mg weight, 2.2 and 22.5 μm thickness, 300 folding endurance, 55.9 and 100% content uniformity, respectively. The Differential Scanning Calorimetry (DSC) showed no stable sample of sumatriptan and metoclopramide in the drug loaded films and revealed amorphous form and transition of hydrate to anhydrous form for metoclopramide. The results showed that the films prepared were fast dissolving. The films (sumatriptan combined with metoclopramide and sumatriptan alone) exhibited very good mucoadhesive properties and shorter retention time (15-30 s). Conclusion: The formulations were found to be suitable candidates for the development of sublingual films for therapeutic uses.
机译:背景:舒马曲坦琥珀酸酯是一种5-HT1受体激动剂,用于治疗偏头痛。由于高的肝脏首过代谢,它显示出低的生物利用度(15%)。本工作旨在配制舒马曲坦与胃复安和舒马曲坦组合的粘膜黏膜舌下膜,以改善治疗效果,患者依从性和生物利用度。方法:采用羟丙基甲基纤维素和丙二醇的粘膜粘附聚合物作为增塑剂,通过溶剂流延法制备舌下膜。这项研究还旨在评估薄膜的物理化学和粘膜粘附特性​​。评估膜的机械强度,耐折性,药物含量均匀性,溶胀,体外停留时间,体外释放,体外生物粘附性和体内粘膜粘附性。结果:它们显示出良好的外观和弹性。最佳聚合物比率的药物是S3(1:2)和SM2(2.7:1:8)。 S3和SM2的薄膜分别显示出10.6和11.01 mg的重量,2.2和22.5μm的厚度,300次耐折性,55.9%和100%的含量均匀性。差示扫描量热法(DSC)显示在载有药物的薄膜中没有舒马普坦和甲氧氯普胺的稳定样品,并显示甲氧氯普胺的无定形形式和水合物向无水形式的转变。结果表明,所制备的薄膜是快速溶解的。薄膜(舒马曲坦联合胃复安和舒马曲坦单独使用)表现出非常好的粘膜粘附特性​​,保留时间更短(15-30 s)。结论:发现该制剂适合开发用于治疗用途的舌下膜。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号